Su, Y., Li, X., Ma, J., Zhao, J., Liu, S., Wang, G., . . . Ge, Y. (2017). Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol.
Citação norma ChicagoSu, Yongwei, et al. "Targeting PI3K, MTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity against AML Ex Vivo." Biochem Pharmacol 2017.
MLA引文Su, Yongwei, et al. "Targeting PI3K, MTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity against AML Ex Vivo." Biochem Pharmacol 2017.
警告：這些引文格式不一定是100％准確.